Ketamine vs. Spravato (Esketamine): Which Is Right for You?

If you're researching rapid-acting treatments for depression, you've probably encountered two options: ketamine and Spravato (esketamine). They sound similar — and they're chemically related — but the practical differences are enormous. Understanding those differences could save you thousands of dollars and months of frustration.

Here's an honest, complete comparison.

What Is Spravato (Esketamine)?

Spravato is the brand name for esketamine, a nasal spray manufactured by Janssen Pharmaceuticals (a Johnson & Johnson subsidiary). It received FDA approval in March 2019, making it the first new class of antidepressant approved in decades — a legitimately significant milestone.

Esketamine is one half of the ketamine molecule. Ketamine is a racemic mixture — it consists of two mirror-image molecules, the S-enantiomer (esketamine) and the R-enantiomer (arketamine). Spravato isolates the S-enantiomer, which was believed to have stronger NMDA receptor binding affinity.

How Spravato is administered: You must visit a certified healthcare facility for every treatment. You self-administer the nasal spray under supervision, then remain at the facility for at least 2 hours of monitoring. You cannot drive yourself home. Sessions are required twice weekly for 4 weeks, then weekly for another 4 weeks, then every 1–2 weeks for maintenance. That's a serious commitment.

What Is Racemic Ketamine (At-Home)?

Racemic ketamine — the form used in at-home programs like Discreet Ketamine — is the full ketamine molecule containing both enantiomers. It has been used safely in clinical settings since FDA approval in 1970 (originally as an anesthetic). It's one of the most studied drugs in medicine.

For at-home treatment, ketamine is formulated as sublingual troches (lozenges) that dissolve under the tongue. You take them at home, on your schedule. The R-enantiomer and S-enantiomer together appear to produce complementary antidepressant and neuroplasticity effects — and decades of clinical use support its safety profile.

Head-to-Head Comparison

The Cost Question: Let's Be Honest

Spravato costs $800–$1,200+ per treatment session without insurance. With the intensive initial schedule (8 sessions in the first month), you're looking at $6,400–$9,600 for the acute phase alone, before maintenance. The drug itself has a list price of approximately $590–$885 per device (two devices per session).

Insurance can cover Spravato — but requirements are strict:

• Must have treatment-resistant depression (typically defined as failure of 2+ antidepressants)
• Must use an in-network provider with a certified REMS program
• Prior authorization is required and often denied initially
• Many plans still require significant cost-sharing

At Discreet Ketamine, our all-inclusive monthly plan is $250/month. That covers your medical evaluation, prescription, medication, and follow-up support. No hidden fees. No surprise bills. No hours in a waiting room.

For most patients, at-home ketamine delivers comparable clinical benefit at roughly 1/20th the cost of Spravato.

What About the FDA Approval?

This is the question we hear most often, and it deserves a direct answer.

Spravato's FDA approval is clinically significant — it means Janssen ran Phase III randomized controlled trials demonstrating efficacy for treatment-resistant depression (and later, MDD with suicidal ideation). That's meaningful.

However, FDA approval does not automatically mean superior efficacy. The approval reflects a regulatory process — not a head-to-head comparison against racemic ketamine. In fact:

• IV ketamine (racemic) has been used in ketamine clinics for over 15 years with extensive real-world data supporting its effectiveness
• Multiple meta-analyses confirm racemic ketamine's antidepressant efficacy at rates comparable to or exceeding Spravato data
• The R-enantiomer in racemic ketamine has its own mechanisms (including sigma receptor activity) that may contribute meaningfully to antidepressant effects
• Sublingual bioavailability is lower than intranasal, but dosing is calibrated accordingly by your provider

The honest answer: both are effective. The choice should be driven by your specific clinical situation, practical constraints, and cost.

Who Should Choose Spravato?

Spravato may be the better choice if:

• You have severe, active suicidal ideation requiring close clinical monitoring
• You have a complex medical situation requiring in-clinic supervision
• Your insurance covers Spravato and makes it cost-effective for you
• You prefer the structure and monitoring of an in-clinic protocol
• You qualify under the FDA indication and want an FDA-approved treatment specifically

Who Should Choose At-Home Ketamine?

At-home ketamine is likely the better choice if:

• Cost is a significant consideration ($250/month vs. $800+/session)
• Convenience matters — you can't commit to twice-weekly clinic visits
• You want privacy and discretion (no clinic, no driving restrictions affecting your schedule)
• You've already tried or been evaluated for Spravato
• You're managing depression with anxiety, PTSD, or OCD as primary or comorbid conditions
• You want to start treatment quickly without insurance authorization delays

The Bottom Line

Spravato is a legitimate, FDA-approved option with real evidence behind it. But for most patients — especially those paying out of pocket — at-home racemic ketamine delivers comparable clinical benefit with dramatically lower cost, greater convenience, and more flexibility.

The best antidepressant treatment is the one you can actually access and afford to maintain. For the vast majority of patients, that's at-home ketamine.

---

Ready to start? Find out if at-home ketamine is right for you with our free 3-minute eligibility check.

Check Your Eligibility →

This article is for educational purposes and does not constitute medical advice. Spravato is a registered trademark of Janssen Pharmaceuticals. Always consult with a qualified healthcare provider about treatment options.